Showing results (161-170 of 510) with videos related to
Sort By:
Pageof 51
Journal of Clinical Immunology|October 1, 1983
Studies of lymphocyte subpopulations in the liver tissue and blood of patients with chronic active hepatitis (CAH)L S Si, T L Whiteside, R R Schade, et al.The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society|May 30, 1998
Endogenous IL-2 in cancer cells: a marker of cellular proliferationT E Reichert, S Watkins, J Stanson, et al.European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
In situ hybridisation for cytokine gene transcripts in the solid tumour microenvironmentD Vitolo, A Kanbour, J T Johnson, et al.Cellular Immunology|June 1, 2000
B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell deathS Lang, Y Atarashi, Y Nishioka, et al.Arthritis and Rheumatism|July 1, 1983
Suppressor cell function and T lymphocyte subpopulations in peripheral blood of patients with progressive systemic sclerosisT L Whiteside, Y Kumagai, A D Roumm, et al.Blood|March 1, 1988
Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remissionA Adler, P A Chervenick, T L Whiteside, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1995
Expression of vitronectin receptor on human NK cells and its role in protein phosphorylation, cytokine production, and cell proliferationH Rabinowich, W C Lin, A Amoscato, et al.Blood|April 1, 1995
Induction of protein tyrosine phosphorylation in human natural killer cells by triggering via alpha 4 beta 1 or alpha 5 beta 1 integrinsH Rabinowich, W C Lin, M Manciulea, et al.International Journal of Cancer|May 28, 1993
Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanomaE Weidmann, E M Elder, M Trucco, et al.Cancer Immunology, Immunotherapy : CII|May 1, 1997
Phase IB trial of picibanil (OK-432) as an immunomodulator in patients with resected high-risk melanomaJ M Kirkwood, J Wilson, T L Whiteside, et al.Pageof 51